428 related articles for article (PubMed ID: 32825530)
1. microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
Kunc M; Popęda M; Niemira M; Szałkowska A; Bieńkowski M; Pęksa R; Łacko A; Radecka BS; Braun M; Pikiel J; Litwiniuk M; Pogoda K; Iżycka-Świeszewska E; Krętowski A; Żaczek AJ; Biernat W; Senkus-Konefka E
Diagnostics (Basel); 2020 Aug; 10(9):. PubMed ID: 32825530
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
3. Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.
Oztemur Islakoglu Y; Noyan S; Aydos A; Gur Dedeoglu B
OMICS; 2018 Nov; 22(11):709-716. PubMed ID: 30388053
[TBL] [Abstract][Full Text] [Related]
4. Novel prognostic and predictive microRNA targets for triple-negative breast cancer.
Turashvili G; Lightbody ED; Tyryshkin K; SenGupta SK; Elliott BE; Madarnas Y; Ghaffari A; Day A; Nicol CJB
FASEB J; 2018 May; ():fj201800120R. PubMed ID: 29812973
[TBL] [Abstract][Full Text] [Related]
5. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
6. A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T; Uehara H; Akao Y; Ibuki N; Komura K; Takahara K; Takai T; Uchimoto T; Saito K; Tanda N; Yoshikawa Y; Minami K; Hirano H; Nomi H; Kato R; Hayashi T; Azuma H
Dis Markers; 2018; 2018():5468672. PubMed ID: 30026881
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
Braza-Boïls A; Salloum-Asfar S; Marí-Alexandre J; Arroyo AB; González-Conejero R; Barceló-Molina M; García-Oms J; Vicente V; Estellés A; Gilabert-Estellés J; Martínez C
Hum Reprod; 2015 Oct; 30(10):2292-302. PubMed ID: 26307093
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
9. Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients.
Barbano R; Pasculli B; Rendina M; Fontana A; Fusilli C; Copetti M; Castellana S; Valori VM; Morritti M; Graziano P; Luigi C; Coco M; Picardo F; Mazza T; Evron E; Murgo R; Maiello E; Esteller M; Fazio VM; Parrella P
Sci Rep; 2017 Mar; 7():45283. PubMed ID: 28345661
[TBL] [Abstract][Full Text] [Related]
10. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
[TBL] [Abstract][Full Text] [Related]
11. MiR-891a-5p as a prognostic marker and therapeutic target for hormone receptor-positive breast cancer.
Zhang Z; Xu L; He L; Wang J; Shi X; Li Z; Shi S; Hou K; Teng Y; Qu X
J Cancer; 2020; 11(13):3771-3782. PubMed ID: 32328182
[No Abstract] [Full Text] [Related]
12. Downregulated miR-17, miR-29c, miR-92a and miR-214 may be related to BCL11B overexpression in T cell acute lymphoblastic leukemia.
He Z; Liao Z; Chen S; Li B; Yu Z; Luo G; Yang L; Zeng C; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e259-e265. PubMed ID: 29749698
[TBL] [Abstract][Full Text] [Related]
13. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
McFall T; McKnight B; Rosati R; Kim S; Huang Y; Viola-Villegas N; Ratnam M
J Biol Chem; 2018 Jan; 293(4):1163-1177. PubMed ID: 29162724
[TBL] [Abstract][Full Text] [Related]
14. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA Expression Profiling on Paired Primary and Lymph Node Metastatic Breast Cancer Revealed Distinct microRNA Profile Associated With LNM.
Elango R; Alsaleh KA; Vishnubalaji R; Manikandan M; Ali AM; Abd El-Aziz N; Altheyab A; Al-Rikabi A; Alfayez M; Aldahmash A; Alajez NM
Front Oncol; 2020; 10():756. PubMed ID: 32509578
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance.
Li C; Yin Y; Liu X; Xi X; Xue W; Qu Y
Oncotarget; 2017 Apr; 8(15):24564-24578. PubMed ID: 28445945
[TBL] [Abstract][Full Text] [Related]
17. Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes.
Nunez Lopez YO; Victoria B; Golusinski P; Golusinski W; Masternak MM
Rep Pract Oncol Radiother; 2018; 23(1):6-20. PubMed ID: 29187807
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
Normann LS; Aure MR; Leivonen SK; Haugen MH; Hongisto V; Kristensen VN; Mælandsmo GM; Sahlberg KK
Sci Rep; 2021 May; 11(1):10893. PubMed ID: 34035375
[TBL] [Abstract][Full Text] [Related]
19. Plasma microRNA Profiles as a Potential Biomarker in Differentiating Adult-Onset Still's Disease From Sepsis.
Hu Q; Gong W; Gu J; Geng G; Li T; Tian R; Yang Z; Zhang H; Shao L; Liu T; Wan L; Jia J; Yang C; Shi Y; Shi H
Front Immunol; 2018; 9():3099. PubMed ID: 30687316
[TBL] [Abstract][Full Text] [Related]
20. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma.
Bowden M; Zhou CW; Zhang S; Brais L; Rossi A; Naudin L; Thiagalingam A; Sicinska E; Kulke MH
Oncotarget; 2017 Aug; 8(33):54331-54344. PubMed ID: 28903345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
